The Use of “Acellbia”—A Biosimilar of Rituximab in Systemic Sclerosis

• Published in: Doklady. Biochemistry and biophysics Vol. 517; no. 1; pp. 140 - 147
• Main Authors: Ananyeva, L. P., Garzanova, L. A., Desinova, O. V., Shayakhmetova, R. U., Starovoitova, M. N., Koneva, O. A., Ovsyannikova, O. B., Glukhova, S. I., Nasonov, E. L.
• Format: Journal Article
• Language: English
• Published: Moscow Pleiades Publishing 01.08.2024; Springer Nature B.V
• Subjects: Antineutrophil cytoplasmic antibodies; Biochemistry; Biological and Medical Physics; Biological products; Biomedical and Life Sciences; Biophysics; Biosimilar Pharmaceuticals - pharmacology; Biosimilar Pharmaceuticals - therapeutic use; Cell therapy; Genetic engineering; Humans; Life Sciences; Lymphocytes B; Molecular Biology; Rheumatoid arthritis; Rituximab; Rituximab - pharmacology; Rituximab - therapeutic use; Scleroderma; Scleroderma, Systemic - drug therapy; Systemic sclerosis; Vasculitis; Russia; rituximab; systemic sclerosis; acellbia

The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One example is ant...